Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Strata Critical Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Strata Critical Medical's regulatory disclosures and financial reporting.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc., formerly Blade Air Mobility, describes its transformation into a focused provider of time‑critical logistics and clinical services for the U.S. transplant and broader healthcare markets. The company now operates two segments, Logistics and Clinical, offering air and ground organ transport, organ placement, surgical recovery, perfusion, preservation and cardiac care services under the Trinity and Keystone brands.
Strata highlights an asset‑light aviation model supplemented by a limited owned aircraft fleet, extensive use of third‑party operators, and proprietary technology to coordinate complex transplant workflows. In 2025 it divested its legacy Passenger business and acquired Keystone Perfusion Services, concentrating on Medical Customers such as transplant centers, hospitals and Organ Procurement Organizations.
The filing emphasizes numerous risks, including continued net losses, integration and divestiture execution, dependence on donor organ availability and reimbursement, operational and aviation safety hazards, climate and geopolitical disruptions, regulatory and privacy obligations, credit‑facility covenants, competition from integrated and device‑based rivals, and the need to recruit and retain specialized clinical, logistics and management talent.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen received an equity award in the form of 64,191 Restricted Stock Units (RSUs) of Class A common stock, reported at a price of $0.00 per share. After this grant, his directly held stake increased to 181,817 shares.
The RSUs will be settled in common shares as they vest. According to the vesting schedule, 6.25% of the RSUs (rounded down to the nearest whole number) will vest every three months after March 8, 2026, with any remaining unvested RSUs vesting on March 8, 2030, as long as he continues serving the company.
Strata Critical Medical, Inc. entered into a new secured, asset-based revolving credit facility of up to $30.0 million with JPMorgan Chase Bank, N.A. and other lenders. The agreement allows the facility to be increased by up to an additional $20.0 million, providing extra borrowing capacity if conditions are met.
The ABL facility matures on January 30, 2029 and will bear interest, at Trinity Air Medical’s election, at an adjusted Term SOFR-based fixed rate plus a 2.00% margin or a one‑month Term SOFR floating rate plus a 2.00% margin. A 0.25% annual commitment fee applies to unused amounts.
The loans are guaranteed by Strata Critical Medical and its subsidiary Strata Critical, Inc. and are secured by first‑priority liens on substantially all personal property of the loan parties. The agreement contains customary covenants and events of default, including a springing minimum fixed charge coverage ratio of 1.05 to 1.00 when availability falls below specified thresholds. Proceeds are intended for working capital and general organizational purposes.
BlackRock, Inc. has reported a passive ownership stake in Strata Critical Medical Inc. Class A stock. BlackRock beneficially owns 4,384,945 shares, representing 5.1% of the outstanding Class A shares. It has sole power to vote 4,316,388 shares and sole power to dispose of 4,384,945 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and are not held for the purpose of changing or influencing control of the company.
Strata Critical Medical, Inc. filed an amended report to update investors on how often it will hold advisory votes on executive pay. At its 2025 annual meeting, stockholders indicated a preference for a non-binding "say-on-pay" vote every year. In response, and in line with the Board’s prior recommendation, the Board’s Compensation Committee decided the company will hold say-on-pay votes on an annual basis.
This approach will continue until the next required vote on the frequency of say-on-pay, which will occur no later than the 2031 annual meeting of stockholders, or until the Board chooses a different frequency. The amendment makes no other changes to the previously reported voting results.